Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2003-11-05
2008-11-25
Devi, S. (Department: 1645)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S139100, C514S008100, C514S921000
Reexamination Certificate
active
07455837
ABSTRACT:
The present invention relates to methods and compositions for the diagnosis and treatment of sepsis. The present invention also provides methods of providing a prognosis to a patient with sepsis. In particular, the present invention relates to compositions and methods for the detection of C5aR expression and the correlation of C5aR expression level with prognosis in sepsis.
REFERENCES:
patent: 5480974 (1996-01-01), Morgan et al.
patent: 5573921 (1996-11-01), Behnke et al.
patent: 6866845 (2005-03-01), Ward et al.
patent: 2005/0244406 (2005-11-01), MacKay
patent: 0 245 993 (1987-11-01), None
Huber-Lang et al. The Faseb J. 16: 1567-1574, Oct. 2002.
Werfel et al. J. Immunol. 157: 1729-1735, 1996.
Rothermel et al. Scand. J. Immunol. 52: 401-410, 2000.
Read et al. J. Exp. Med. 182: 267-272, 1995.
Hollenberg et al. Am. J. Respir. Crit. Care Med. 164: 891-895, Sep. 2001.
Deitch EA. Shock 24: Suppl. 1, 19-23, 2005.
Hyde et al. Infect. Immun. 58: 519-624, 1990.
Hotchkiss et al. PNAS 96: 14541-14546, 1999.
Mandecki et al., “Chemical synthesis of a gene encoding the human complement fragment C5a and its expression inEscherichia,” PNAS U S A. Jun.;82(11):3543 7(1985).
Reidemann et al., “Increased C5a receptor expression in sepsis,” (2002) J. Clin. Invest. 110:101-108.
Solomkin et al., “Neutrophil dysfunction in sepsis. II. Evidence for the role of complement activation products in cellular deactivation,” Surgery 90:319-327, (1981).
Van Epps, et al., “Relationship of C5a receptor modulation to the functional responsiveness of human polymorphonuclear leukocytes to C5a,” J. Immunol. 150:246-252 (1993).
Ward and Becker, “The deactivation of rabbit neutrophils by chemotactic factor and the nature of the activatable esterase,” J. Exp. Med. 127:693-709 (1968).
Olson et al., “The role of C5 in septic lung injury,” Ann. Surg. 202:771-776 (1985).
Wong et al., “Small molecular probes for G-protein-coupled C5a receptors: conformationally constrained antagonists derived from the C terminus of the human plasma protein C5a,” (1998) J. Med. Chem. 41,3417-3425.
Mollison et al., (1992) FASEB J. 6,A2058.
Drapeau et al., “Synthetic C5a receptor agonists. Pharmacology, metabolism and in vivo cardiovascular and hematologic effects,” (1993) Biochem. Pharmacol. 45,1289-1299.
Konteatis et al., “Development of C5a receptor antagonists. Differential loss of functional responses,” (1994) J. Immunol. 153,4200-4205.
Woodruff et al., “Species dependence for binding of small molecule agonist and antagonists to the C5a receptor on polymorphonuclear leukocytes,” Inflammation 25, 171-7. (2001).
Haynes et al., “Inhibition of C5a-induced neutrophil chemotaxis and macrophage cytokine production in vitro by a new C5a receptor antagonist,” Biochem Pharmacol 60, 729-33. (2000).
Strachan et al., “A new small molecule C5a receptor antagonist inhibits the reverse-passive Arthus reaction and endotoxic shock in rats,” J Immunol 164, 6560-5. (2000).
Paczkowski et al., “Pharmacological characterization of antagonists of the C5a receptor,” Br J Pharmacol 128, 1461-6 (1999).
Finch et al., J Med Chem 42, 1965-74. (1999).
Strachan et al., “Inhibition of immune-complex mediated dermal inflammation in rats following either oral or topical administration of a small molecule C5a receptor antagonist,” Br J Pharmacol 134, 1778-86. (2001).
Short et al., “Effects of a new C5a receptor antagonist on C5a- and endotoxin-induced neutropenia in the rat,” (1999) Br. J. Pharmacol. 126,551-554.
Mulligan et al., “Requirement and role of C5a in acute lung inflammatory injury in rats,” (1996) J. Clin. Invest. 98,503-512.
Larsen et al., “The pulmonary response of C5 sufficient and deficient mice to immune complexes,” (1981) Am. Rev. Respir. Dis. 123,434-439.
Koch et al., (1997) Shock 7,42-48.
Short et al., “Response-selective C5a agonists: differential effects on neutropenia and hypotension in the rat,” (1999) Br. J. Pharmacol. 128,511-514.
Goya et al., “Immunologic assessment of host defense impairment in patients with septic multiple organ failure: relationship between complement activation and changes in neutrophil function,” (1994) Surgery 115,145-155.
Hecke et al., “Circulating complement proteins in multiple trauma patients—correlation with injury severity, development of sepsis, and outcome,” (1997) Crit. Care Med. 25,2015-2024.
Czermak et al., “Protective effects of C5a blockade in sepsis,” (1999) Nature Med.. 5,788-792.
Guo Renfeng
Huber-Lang Markus
Riedemann Niels C.
Sarma J. Vidya
Ward Peter A.
Casmier Jones, S.C.
Devi S.
The Regents of the University of Michigan
LandOfFree
Compositions and methods for the diagnosis and treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the diagnosis and treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the diagnosis and treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4021133